0.00
Allakos Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.
See More
Previous Close:
$0.3291
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$29.69M
Revenue:
-
Net Income/Loss:
$-166.14M
P/E Ratio:
0.00
EPS:
-1.92
Net Cash Flow:
$-139.92M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
Allakos Inc Stock (ALLK) Company Profile
Name
Allakos Inc
Sector
Industry
Phone
650-597-5002
Address
825 INDUSTRIAL ROAD, SAN CARLOS, CA
Compare ALLK with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ALLK
Allakos Inc
|
0.00 | 29.69M | 0 | -166.14M | -139.92M | -1.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.05 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
555.95 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.81 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Allakos Inc Stock (ALLK) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-17-24 | Downgrade | Jefferies | Buy → Hold |
Jan-16-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Dec-18-23 | Upgrade | William Blair | Mkt Perform → Outperform |
Dec-08-23 | Resumed | Jefferies | Buy |
Sep-27-23 | Initiated | JMP Securities | Mkt Outperform |
May-12-23 | Upgrade | Jefferies | Hold → Buy |
Mar-07-23 | Initiated | Piper Sandler | Overweight |
Sep-12-22 | Downgrade | SMBC Nikko | Neutral → Underperform |
Dec-22-21 | Downgrade | BofA Securities | Buy → Underperform |
Dec-22-21 | Downgrade | Cowen | Outperform → Market Perform |
Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
Dec-22-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Dec-22-21 | Downgrade | William Blair | Outperform → Mkt Perform |
Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
Jul-15-21 | Initiated | Cowen | Outperform |
May-18-21 | Initiated | H.C. Wainwright | Buy |
Feb-24-21 | Initiated | Cantor Fitzgerald | Overweight |
Jan-15-21 | Initiated | BofA Securities | Buy |
Dec-21-20 | Initiated | SVB Leerink | Outperform |
Feb-27-20 | Initiated | Barclays | Underweight |
Feb-04-20 | Resumed | Goldman | Neutral |
Aug-13-18 | Initiated | Goldman | Neutral |
Aug-13-18 | Initiated | Jefferies | Buy |
Aug-13-18 | Initiated | William Blair | Outperform |
View All
Allakos Inc Stock (ALLK) Latest News
ALLKAllakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results - mx.advfn.com
Jane Street Group LLC Has $122,000 Stock Position in Allakos Inc. (NASDAQ:ALLK) - Defense World
Allakos Inc. (NASDAQ:ALLK) Position Lowered by Millennium Management LLC - Defense World
Allakos Inc. (NASDAQ:ALLK) Stock Holdings Lowered by Deutsche Bank AG - Defense World
TANG CAPITAL MANAGEMENT LLC Significantly Reduces Holdings in Al - GuruFocus
TANG CAPITAL MANAGEMENT LLC Significantly Reduces Holdings in Allakos Inc - GuruFocus
Allakos stock hits 52-week low at $0.3 amid market challenges - MSN
Allakos completes merger with Concentra Biosciences By Investing.com - Investing.com South Africa
Allakos Completes Merger with Concentra Biosciences - TipRanks
Allakos completes merger with Concentra Biosciences - Investing.com
Allakos Inc.(NasdaqGS: ALLK) dropped from S&P TMI Index - marketscreener.com
Allakos Inc. (NASDAQ:ALLK) Shares Sold by Barclays PLC - Defense World
Allakos Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
ALLK Shares Experience Decline in Value - knoxdaily.com
Renaissance Technologies LLC Has $1.02 Million Position in Allakos Inc. (NASDAQ:ALLK) - Defense World
Allakos Inc. (NASDAQ:ALLK) Short Interest Update - Defense World
Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Press Release Distribution & PR Platform - ACCESS Newswire
ALLK NOTICE: ROSEN, THE FIRST FILING FIRM, Reminds Allakos Inc. Investors of Important Deadline in Securities Class Action Seeking Recovery of Investor Losses; Those with Losses in Excess of $100K Should Contact FirmALLK - ACCESS Newswire
Checking in on Allakos Inc (ALLK) after recent insiders movement - knoxdaily.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COOP, HMST, ALLK, OPOF on Behalf of Shareholders - PR Newswire
Allakos Inc (ALLK) Recovers 48.96% From Low: Are We There Yet? - stocksregister.com
Allakos And 2 Other Promising Penny Stocks To Watch - simplywall.st
Short Interest in Allakos Inc. (NASDAQ:ALLK) Decreases By 13.9% - Defense World
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Allakos Inc.ALLK - PR Newswire
Concentra Biosciences, LLC entered into an agreement to acquire Allakos Inc. for $31 million. - marketscreener.com
Allakos Inc Inc. (ALLK) Price Performance: A Technical Analysis Perspective - investchronicle.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Allakos, Inc. (ALLK) - TradingView
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Tang Capital’s Concentra nabs a win, making a deal to buy Allakos - Endpoints News
Allakos to be acquired by Concentra Biosciences for 33c per share in cash - TipRanks
ALLK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Allakos Inc. Is Fair to Shareholders - The Joplin Globe
Allakos to Be Acquired by Concentra Biosciences for $0.33 per Share - MarketScreener
Allakos Announces Merger Agreement with Concentra Biosciences - TipRanks
Shareholder Alert: The Ademi Firm Investigates Whether Allakos Inc. Is Obtaining a Fair Price for Its Public Shareholders - Bluefield Daily Telegraph
Allakos agrees to Concentra Biosciences acquisition - Investing.com
Allakos surges on reverse merger deal with Concentra Biosciences - Seeking Alpha
Allakos to Be Acquired for 33 Cents a Share - MarketWatch
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share - The Manila Times
Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences - MarketScreener
Allakos (ALLK) Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share - StreetInsider
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in - Bluefield Daily Telegraph
Biotech Deal Alert: Concentra Biosciences Acquires AllakosKey Terms Revealed - Stock Titan
ALLK ALERT: ROSEN, A LEADING FIRM, Reminds Allakos Inc. Investors of Important May 11th Deadline in Securities Class Action First Filed By Firm- ALLK - ACCESS Newswire
Allakos stock plunges to 52-week low of $0.23 amid market challenges By Investing.com - Investing.com South Africa
Allakos stock plunges to 52-week low of $0.23 amid market challenges - Investing.com Australia
Shareholder Alert: The Ademi Firm Investigates Whether LENSAR, Inc. is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Shareholder Alert: The Ademi Firm investigates whether Optinose, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire
Allakos Inc Stock (ALLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):